Abstract B155: A phase I study of the MEK inhibitor GSK1120212 (GSK212) in combination with PI3K/mTOR inhibitor GSK2126458 (GSK458) in patients with advanced solid tumors.

Mapping Intimacies ◽

10.1158/1535-7163.targ-11-b155 ◽

2011 ◽

Author(s):

Juneko E. Grilley-Olson ◽

Phillip Bedard ◽

Angelica Fasolo ◽

Samuel C. Blackman ◽

Leanne Cartee ◽

...

Keyword(s):

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Mtor Inhibitor ◽

Mek Inhibitor ◽

Advanced Solid Tumors

Download Full-text

Abstract LB-C17: A phase I study of everolimus (mTOR inhibitor) in combination with vandetanib (multikinase inhibitor of VEGFR, EGFR, and RET) in advanced solid tumors including molecularly matched aberrations

10.1158/1535-7163.targ-15-lb-c17 ◽

2015 ◽

Author(s):

Tina Cascone ◽

Kenneth R. Hess ◽

Sarina Piha-Paul ◽

David S. Hong ◽

Michael Roxas ◽

...

Keyword(s):

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Mtor Inhibitor ◽

Advanced Solid Tumors ◽

Multikinase Inhibitor

Download Full-text

A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumors

Investigational New Drugs ◽

10.1007/s10637-020-00936-z ◽

2020 ◽

Vol 38 (6) ◽

pp. 1755-1762 ◽

Author(s):

Mojun Zhu ◽

Julian R. Molina ◽

Grace K. Dy ◽

Gary A. Croghan ◽

Yingwei Qi ◽

...

Keyword(s):

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Mtor Inhibitor ◽

Kinase Inhibitor ◽

Advanced Solid Tumors

Download Full-text

Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology ◽

10.1007/s00280-011-1788-4 ◽

2011 ◽

Vol 69 (4) ◽

pp. 1099-1105 ◽

Author(s):

Yoshitaka Seki ◽

Noboru Yamamoto ◽

Yosuke Tamura ◽

Yasushi Goto ◽

Takashi Shibata ◽

...

Keyword(s):

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Mtor Inhibitor ◽

Japanese Patients ◽

Advanced Solid Tumors

Download Full-text

303 A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumors

European Journal of Cancer ◽

10.1016/s0959-8049(16)30169-1 ◽

2015 ◽

Vol 51 ◽

pp. S55 ◽

Author(s):

V. De Weger ◽

A. Varga ◽

M. De Jonge ◽

M. Langenberg ◽

M. Mergui-Roelvink ◽

...

Keyword(s):

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Mek Inhibitor ◽

Advanced Solid Tumors

Download Full-text

A phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor Everolimus (RAD001) in patients (pts) with advanced solid tumors

Journal of Clinical Oncology ◽

10.1200/jco.2005.23.16_suppl.3007 ◽

2005 ◽

Vol 23 (16_suppl) ◽

pp. 3007-3007 ◽

Author(s):

J. Tabernero ◽

F. Rojo ◽

H. Burris ◽

E. Casado ◽

T. Macarulla ◽

...

Keyword(s):

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Mtor Inhibitor ◽

Advanced Solid Tumors

Download Full-text

1448 ORAL Molecular pharmacodynamic (MPD) phase I study with serial tumor and skin biopsies of the oral mTOR inhibitor Everolimus (E, RAD001) at different doses and schedules in patients (pts) with advanced solid tumors

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(05)81739-2 ◽

2005 ◽

Vol 3 (2) ◽

pp. 419

Keyword(s):

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Mtor Inhibitor ◽

Advanced Solid Tumors ◽

Skin Biopsies ◽

Different Doses

Download Full-text

A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.3020 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. 3020-3020 ◽

Author(s):

A. J. Wagner ◽

J. C. Bendell ◽

S. Dolly ◽

J. A. Morgan ◽

J. A. Ware ◽

...

Keyword(s):

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Mtor Inhibitor ◽

Advanced Solid Tumors

Download Full-text

526 A Phase I study of the dual, intravenous (IV) phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor PF-05212384 in combination with irinotecan in patients (pts) with colorectal cancer (CRC) and other advanced solid tumors

European Journal of Cancer ◽

10.1016/s0959-8049(14)70652-5 ◽

2014 ◽

Vol 50 ◽

pp. 171

Author(s):

Z. Wainberg ◽

J. Tabernero ◽

M.A. Maqueda ◽

S. Leong ◽

G. Del Conte ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Mtor Inhibitor ◽

Mammalian Target Of Rapamycin ◽

Target Of Rapamycin ◽

Advanced Solid Tumors ◽

Phosphatidylinositol 3 Kinase ◽

Phosphatidylinositol 3

Download Full-text

Abstract B279: A phase I study determining the safety and tolerability of combination therapy with Pazopanib (P), a VEGFR/PDGFR/Raf inhibitor, and GSK1120212 (Trametinib: T), a MEK inhibitor, in advanced solid tumors with expansion cohorts in advanced differentiated thyroid cancer (DTC), cholangiocarcinoma (ChCA), and soft tissue sarcoma (STS).

10.1158/1535-7163.targ-13-b279 ◽

2013 ◽

Author(s):

Nilofer Azad ◽

Douglas Ball ◽

Steven Sherman ◽

Michelle Rudek ◽

Gerald Falchook ◽

...

Keyword(s):

Thyroid Cancer ◽

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Combination Therapy ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Differentiated Thyroid Cancer ◽

Mek Inhibitor ◽

Advanced Solid Tumors

Download Full-text

Abstract A48: Phase I study of Everolimus (mTOR inhibitor) in combination with Vandetanib (multikinase inhibitor of EGFR,VEGFR,RET) in children, adolescents, and young adults with advanced solid tumors

10.1158/1538-7445.pedca15-a48 ◽

2016 ◽

Author(s):

Hatel Rana Moonat ◽

Michael Roxas ◽

Winston W. Huh ◽

Cynthia E. Herzog ◽

Sarina Piha-Paul ◽

...

Keyword(s):

Young Adults ◽

Phase I ◽

Solid Tumors ◽

Phase I Study ◽

Mtor Inhibitor ◽

Adolescents And Young Adults ◽

Advanced Solid Tumors ◽

Multikinase Inhibitor

Download Full-text